Infectious Vaccines Partnering Terms and Agreements - PowerPoint PPT Presentation

About This Presentation
Title:

Infectious Vaccines Partnering Terms and Agreements

Description:

Bharat Book Presents The present report on "Infectious Vaccines Partnering Terms and Agreements” The Infectious Vaccines Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. – PowerPoint PPT presentation

Number of Views:63

less

Transcript and Presenter's Notes

Title: Infectious Vaccines Partnering Terms and Agreements


1
Infectious Vaccines Partnering Terms and
Agreements
One-Stop Shop for Business Information
2
Summary
The Infectious Vaccines Partnering Terms and
Agreements report provides a detailed
understanding and analysis of how and why
companies enter infectious vaccines partnering
deals. The majority of deals are development
stage whereby the licensee obtains a right or an
option right to license the licensors vaccine
technology. These deals tend to be
multicomponent, starting with collaborative RD,
and commercialization of outcomes. The report
also includes adjuvant deals and alliances. This
report provides details of the latest infectious
vaccines agreements announced in the healthcare
sectors. Understanding the flexibility of a
prospective partners negotiated deals terms
provides critical insight into the negotiation
process in terms of what you can expect to
achieve during the negotiation of terms. Whilst
many smaller companies will be seeking details of
the payments clauses, the devil is in the detail
in terms of how payments are triggered contract
documents provide this insight where press
releases and databases do not. 
3
This report contains a comprehensive listing of
all infectious vaccines partnering deals
announced since January 2007, including financial
terms where available, including over 700 links
to online deal records of actual infectious
vaccines partnering deals as disclosed by the
deal parties. In addition, where available,
records include contract documents as submitted
to the Securities Exchange Commission by
companies and their partners. Contract documents
provide the answers to numerous questions about a
prospective partners flexibility on a wide range
of important issues, many of which will have a
significant impact on each partys ability to
derive value from the deal.
4
For example, analyzing actual company deals and
agreements allows assessment of the
following What is actually granted by the
agreement to the partner company?What
exclusivity is granted? What are the precise
rights granted or optioned? What is the payment
structure for the deal? How aresalesand payments
audited? What is the deal term? How are the key
terms of the agreement defined? How are IPRs
handled and owned? Who is responsible for
commercialization? Who is responsible for
development, supply, and manufacture?
5
How is confidentiality and publication
managed?How are disputes to be resolved?Under
what conditions can the deal be terminated?What
happens when there is a change of ownership?What
sublicensing and subcontracting provisions have
been agreed?Which boilerplate clauses does the
company insist upon?Which boilerplate clauses
appear to differ from partner to partner or deal
type to deal type?Which jurisdiction does the
company insist upon for agreement law?The
initial chapters of this report provide an
orientation of infectious vaccines dealmaking and
business activities. Chapter 1 provides an
introduction to the report, whilst chapter 2
provides an overview of the trends in infectious
vaccines dealmaking since 2007, including details
of average headline, upfront, milestone and
royalty terms.
6
Table of Contents
Executive SummaryChapter 1 IntroductionChapte
r 2 Trends in infectives vaccine
dealmaking2.1. Introduction2.2. Infectious
Vaccines partnering over the years2.3. Bigp
harma Infectious Vaccines dealmaking
activity2.4. Most active in Infectious Vaccines
partnering2.5. Infectious Vaccines partnering by
deal type2.6. Infectious Vaccines partnering by
stage of development2.7. Infectious Vaccines
partnering by infectives indication2.8.
Infectious Vaccines partnering by vaccine and
adjuvant indication2.9. Disclosed deal terms for
Infectious Vaccines partnering
7
Related Reports
  • World Vaccines Market 2013-2023
  • Competitor Analysis Staphylococcus aureus
    Vaccines and Therapeutics (Antibodies,
    Antibiotics, Anti-Infectives)
  • Menveo (Meningococcal Vaccines) - Forecast and
    Market Analysis to 2022
  • NeisVac-C (Meningococcal Vaccines) - Forecast and
    Market Analysis to 2022

8
Custom Research
  • Incase the reports dont match your
    requirement then we can do a Custom Research for
    you. Our multifarious capabilities, cross-sector
    expertise and detailed knowledge of various
    markets, put us at a unique position to take up
    Custom Research demands of yours. We provide the
    specifications of the custom research job to a
    dedicated team comprising of researchers,
    analysts and industry experts, who have close
    experience and understanding of global markets,
    competitive landscapes, various business models,
    market shares, drivers, restraints and
    benchmarks.
  • http//www.bharatbook.com/customResearch.asp

9
For More Information You Can Visit
  • http//www.bharatbook.com/healthcare-market-resear
    ch-reports/infectious-vaccines-partnering-terms-an
    d-agreements.html

Request Sample Pages
Contact Us-Call India 91-22-27810772/73 Call
USA/Canada (Toll Free) 1-866-279-8368 For Live
Chat - http//bit.ly/19m3TU4
Follow/Like Us on-
Write a Comment
User Comments (0)
About PowerShow.com